Jpmorgan Chase & CO Biomea Fusion, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BMEA
# of Institutions
104Shares Held
17.8MCall Options Held
1.68MPut Options Held
410K-
Cormorant Asset Management, LP Boston, MA3.57MShares$24.7 Million2.53% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$16.2 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.11MShares$14.6 Million0.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$9.69 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.38MShares$9.55 Million0.01% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $203M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...